Following today’s volume and price action, could JAN have a short position that exceeds the 2.38M shares in the float? One Redditor thinks so...
Citius Pharma (CTXR) Prepares for Phase III Data Release at the End of This Month and the Potential Catalysts are Lining Up.
(NASDAQ: CTXR) is now up well over 200% since our December report. Citius Pharma (CTXR) Prepares for Phase III Data Release at the End of This Month a...
Do you Consider ESG Criteria Before you Invest in a Company? New Report will be Released Tomorrow on One of our Favorite NASDAQ Stocks
Good day everyone and welcome to all our new members, We continue to scour the markets for companies that present with the opportunity for near-term g...
Jupiter Wellness (JUPW) has an Accretive Acquisition in Process, is Generating Revenue and Conducting Clinicals for CBD Medicine
Jupiter Wellness (JUPW) has an Accretive Acquisition in Process, is Generating Revenue and Conducting Clinicals for CBD Medicine Good day everyone, We...
Are IPOs Worth Investing in at the Start or is There a Sweet Spot After the Initial Capital Raise?
New report highlighting a recent IPO coming Tuesday June 1st, 2021 at market open. Good day everyone, The market indices clawed back som...
AIkido Pharma (NASDAQ: AIKI) a move to current book value ($1.73) represents a 60% gain from the current $1.09/share
Aikido Pharma (AIKI) Shares Have a Lot of Value Built in on Top of Near-Term Milestones Anticipated AIKI Market cap is a ridiculous $10M less than cas...
Record Earnings Reports and Massive Spending Programs Seem Like a Strong Economy. New NASDAQ Report Coming Tomorrow 5/20/21 at Market Open
Good day everybody, Earnings are strong. Many companies in the S&P are reporting performances beyond the expectations of analysts. In fact, some o...
Should Inflation be Something to Panic Over? Or Just a Natural Result of a Growing Economy
Report coming tomorrow at market open Good day everyone, The past week was interesting to say the least. The NASDAQ slid all the way through Thursday ...
Updates 22nd Century Group (NYSE: XXII) Citius Pharma (NASDAQ: CTXR) and Genprex (NASDAQ: GNPX)
Update 05/13/2021 (NASDAQ: RELI) our April 19th, 2021 report at $3.10/share announced an acquisition today and has broken above the 50DMA crossing $4....
Genprex, Inc. (NASDAQ: GNPX) Genetics Sector Working with Big Pharma and Generating Big Potential
Genprex (GNPX) Pipeline Could Impact or Eradicate Cancer and Diabetes with Promising Gene Development Possible short squeeze here. Since February, ...
